EUVIMEDEUVIMED entdecken
Crossref

LI-RADS for diagnosing hepatocellular carcinoma by contrast-enhanced US with SonoVue and Sonazoid—a single center prospective study

Chen Lin, Xiao-Huan Yang, Hong-Yan Zhai, Xin-Yuan Zhu, Gui-Ming Zhou

Abdominal Radiology · 2025

DOI: 10.1007/s00261-025-04881-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Abdominal Radiology, 2025. Verfasst von Chen Lin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Tianjin Medical University General Hospital, Tianjin, China. Hauptthemen laut MEDLINE: Contrast Media, Liver Neoplasms, Carcinoma, Hepatocellular, Phospholipids. Die Arbeit nennt 28 Literaturangaben. Gefördert von: China International Medical Foundation, Tianjin excellent science and technology special correspondent 2023.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To compare the diagnostic performance of two algorithms for HCC diagnosis: SonoVue-CEUS based on CEUS LI-RADS version 2017 and a modified algorithm incorporating Kupffer-phase findings for Sonazoid-CEUS. METHODS: This single center prospective study enrolled high-risk patients for HCC. Each participant underwent SonoVue-CEUS and Sonazoid-CEUS. Each liver observation was assigned two LI-RADS categories according to each algorithm: SonoVue-CEUS LI-RADS and modified Sonazoid-CEUS LI-RADS. For the latter method, observations at least 10 mm with non-rim arterial phase hyperenhancement were upgraded LR-4 to LR-5 if there was no washout with a Kupffer defect and were reassigned LR-M to LR-5 if there was early washout with mild Kupffer defect. The reference standard was pathologic confirmation. RESULTS: Overall, 66 patients (mean age, 61.2 years ± 10.9; 54 male patients, 12 female patients) with 66 observations (mean size, 31 mm ± 16) were eventually enrolled. The results of Sonazoid-CEUS LI-RADS showed significant changes in sensitivity (82% vs. 65%, p < 0.001), accuracy (85% vs. 71%, p < 0.001) compared with the SonoVue-CEUS LI-RADS. There was no significant difference in specificity (93% vs. 87%, p = 0.26). CONCLUSION: When incorporating Kupffer-phase findings, Sonazoid-CEUS LI-RADS had higher sensitivity without loss of specificity compared with SonoVue-CEUS LI-RADS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Contrast MediaLiver NeoplasmsCarcinoma, HepatocellularPhospholipidsOxidesSulfur HexafluorideFerric CompoundsIronImage EnhancementHumansFemaleMaleProspective StudiesMiddle AgedUltrasonographyAlgorithmsSensitivity and SpecificityAged

Stichwörter der Autor:innen

CEUSLI-RADSSensitivitySonazoidSonoVue

Substanzen

Contrast MediaSonazoidPhospholipidsOxidesSulfur HexafluorideFerric CompoundsIroncontrast agent BR1

Autor:innen und Institutionen

  • Tianjin Medical University General Hospital, Tianjin, China.
  • Central Hospital Affiliated to Shandong First Medical University, Jinan, China.
  • Tianjin Medical University General Hospital, Tianjin, China. kuailezhuxinyuan@163.com.
  • Tianjin Medical University General Hospital, Tianjin, China. zhouguiming_GH@163.com.

Förderung

  • China International Medical Foundation
  • Tianjin excellent science and technology special correspondent 2023

Zitieren

APA

Lin, C., Yang, X. H., Zhai, H. Y., Zhu, X. Y., & Zhou, G. M. (2025). LI-RADS for diagnosing hepatocellular carcinoma by contrast-enhanced US with SonoVue and Sonazoid—a single center prospective study. Abdominal Radiology. https://doi.org/10.1007/s00261-025-04881-4

Vancouver

Lin C, Yang XH, Zhai HY, Zhu XY, Zhou GM. LI-RADS for diagnosing hepatocellular carcinoma by contrast-enhanced US with SonoVue and Sonazoid—a single center prospective study. Abdominal Radiology. 2025. doi:10.1007/s00261-025-04881-4

BibTeX
@article{Lin2025,
  author = {Lin, Chen and Yang, Xiao-Huan and Zhai, Hong-Yan and Zhu, Xin-Yuan and Zhou, Gui-Ming},
  title = {LI-RADS for diagnosing hepatocellular carcinoma by contrast-enhanced US with SonoVue and Sonazoid—a single center prospective study},
  journal = {Abdominal Radiology},
  year = {2025},
  doi = {10.1007/s00261-025-04881-4}
}
Kostenlos starten →